Beta Bionics (BBNX) news
Recent news
Beta Bionics sees year gross margin 58.5%-59.5%, saw 57.5%-59.5%
AInvest Wire · Jul 29, 2026Beta Bionics still sees year total revenue about $131M to $136M
AInvest Wire · Jul 29, 2026Beta Bionics 2Q net loss $23.4M vs. loss $16.9M Y/Y
Beta Bionics, Inc. (Nasdaq: BBNX) reported net loss of $23.4 million , compared to a net loss of $16.9 million in the same period of 2024, according to its financial results released on July 29, 2025. The increase in the net loss reflects higher operating expenses, driven by continued investment in…
AInvest Wire · Jul 29, 2026Beta Bionics expects to fully commercialize Mint by 2Q of 2027
Beta Bionics (NASDAQ:BBNX) has outlined plans to commercialize its Mint patch pump by the second quarter of 2027, according to recent disclosures from the company. The Mint system, a two-part patch pump design, is intended to compete with existing patch pump offerings in the insulin delivery…
AInvest Wire · May 21, 2026ImportantBeta Bionics targets $695 million valuation in upsized US IPO
Beta Bionics targets $695 million valuation in upsized US IPO California-based insulin delivery device manufacturer Beta Bionics is poised to make a significant splash in the U.S. public market, targeting an IPO valuation of $695 million [1]. This ambitious figure reflects the optimism surrounding…
AInvest Wire · Jan 28, 2025Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.